Gilead Sciences (Australia)

Plain language summary of the ZUMA-5 study of axicabtagene ciloleucel for people with relapsed or refractory slow-growing non-Hodgkin lymphoma

What is this summary about? This is a summary of a clinical study called ZUMA-5. The study looked at how well the cancer treatment axicabtagene ciloleucel (axi-cel) worked for people with indolent non-Hodgkin lymphoma (iNHL), including follicular lymphoma (FL) and marginal zone l...

Impact on health outcomes of treating all eligible large B-cell lymphoma patients with axicabtagene ciloleucel in Portugal – A modeling approach

AIM: This study aimed to quantify the health benefits that can be achieved by treating axicabtagene-ciloleucel (axi-cel)-eligible large B-cell lymphoma patients with axi-cel instead of historical standard of care (hSoC) in Portugal. "Estimated Opportunity Lost" quantified the dif...